Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 825 INDUSTRIAL ROAD, SUITE 500 SAN CARLOS CA 94070 |
Tel: | N/A |
Website: | https://www.allakos.com |
IR: | See website |
Key People | ||
Adam Tomasi President | Robert D. Alexander Chief Executive Officer, Director | Baird Radford Chief Financial Officer |
Margaret Nell Fitzgerald Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary | Craig Paterson Chief Medical Officer |
Business Overview |
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company's most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria. |
Financial Overview |
For the three months ended 31 March 2024, Allakos Inc revenues was not reported. Net loss increased 68% to $71.1M. Higher net loss reflects Research and Development - Balancing increase of 18% to $33.6M (expense), Interest income decrease of 26% to $2M (income), Other expense, net increase of 100% to $72K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.49 to -$0.81. |
Employees: | 131 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Mar 31, 2024 |
EBITDA (TTM): | -$191.02M as of Mar 31, 2024 |
Net annual income (TTM): | -$214.44M as of Mar 31, 2024 |
Free cash flow (TTM): | -$119.21M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 87,750,000 as of Mar 31, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |